Core Viewpoint - The company Jiahe Meikang (688246.SH) announced a share reduction plan by its shareholder, Saifu Puxin, due to liquidity needs, intending to sell up to 2.6725 million shares, which represents 1.94% of the company's total share capital [1] Group 1 - The shareholder Saifu Puxin plans to reduce its holdings through centralized bidding [1] - The planned share reduction will occur within 90 days after the announcement, starting from the third trading day [1] - The maximum number of shares to be sold is 2.6725 million [1]

Core Viewpoint - The company Jiahe Meikang (688246.SH) announced a share reduction plan by its shareholder, Saifu Puxin, due to liquidity needs, intending to sell up to 2.6725 million shares, representing 1.94% of the total share capital [1] Group 1 - The shareholder Saifu Puxin plans to reduce its holdings through centralized bidding [1] - The reduction will occur within 90 days after the announcement, starting from the third trading day following the disclosure [1] - The maximum number of shares to be sold is 2.6725 million [1]

2024年1至12月份，嘉和美康的营业收入构成为：医疗信息化行业占比99.73%，其他行业占比0.27%。 （记者 曾健辉） 每经AI快讯，嘉和美康（SH 688246，收盘价：29.9元）9月10日晚间发布公告称，截至本公告披露日， 嘉和美康（北京）科技股份有限公司股东苏州赛富璞鑫医疗健康产业投资中心（有限合伙）持有公司股 份约267万股，占公司股份总数的1.94%。相关股份为嘉和美康首次公开发行并上市前取得的股份，且 已于2022年12月14日起上市流通。公司于2025年9月10日收到赛富璞鑫出具的《关于股东减持计划的告 知函》，因股东流动性需求，股东赛富璞鑫计划根据市场情况通过集中竞价方式减持其持有的公司股份 不超过约267万股，即不超过公司总股本的1.94%。自本公告披露之日起3个交易日后的90天内进行。赛 富璞鑫系已在中国证券投资基金业协会完成备案的私募基金，并向中国证券投资基金业协会成功申请了 创业投资基金股东的减持政策，且截至公司首次公开发行上市日，赛富璞鑫的投资期限超过48个月但不 满60个月，赛富璞鑫适用连续30日内集中竞价交易减持的股份总数不超过公司股份总数的1%，通过大 宗交易减持的股份 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2025-062 嘉和美康（北京）科技股份有限公司 重要内容提示： 股东持有的基本情况 截至本公告披露日，嘉和美康（北京）科技股份有限公司（以下简称"嘉和 美康"或"公司"）股东苏州赛富璞鑫医疗健康产业投资中心（有限合伙）（以下 简称"赛富璞鑫"）持有公司股份 2,672,492 股，占公司股份总数的 1.94%。上 述股份为嘉和美康首次公开发行并上市前取得的股份，且已于 2022 年 12 月 14 日起上市流通。 减持计划的主要内容 公司于 2025 年 9 月 10 日收到赛富璞鑫出具的《关于股东减持计划的告知函》， 因股东流动性需求，股东赛富璞鑫计划根据市场情况拟通过集中竞价方式减持其 持有的公司股份不超过 2,672,492 股，即不超过公司总股本的 1.94%。自本公告 披露之日起 3 个交易日后的 90 天内进行。根据《上市公司创业投资基金股东减 持股份的特别规定（2020 年修订）》《上海证券交易所上市公司创业投资基金股 东减持股份实施细则（2020 年修订）》的有关规定，赛富璞鑫系已在中国证券投 资基金业协会完成备案的私募基金，并向中国证 ...

人民财讯9月10日电，嘉和美康(688246)9月10日晚间公告，持股1.94%的股东苏州赛富璞鑫医疗健康产 业投资中心(有限合伙)(简称"赛富璞鑫")计划根据市场情况拟通过集中竞价方式减持其持有的公司股份 不超过267.25万股，即不超过公司总股本的1.94%。 ...

Group 1 - Huaneng Power announced that its shareholder Hunan Energy Group plans to reduce its stake by up to 20.31 million shares, not exceeding 1% of the total share capital [1] - Ankai Bus reported a production of 1,012 buses in August, a year-on-year increase of 68.06%, with sales of 773 buses, up 46.95% year-on-year [1] - Lianhuan Pharmaceutical received a drug registration certificate for Famotidine injection, classified as a Class 3 chemical drug [1][2] Group 2 - Dongrui Co. reported sales of 94,800 pigs in August, generating revenue of 160 million yuan, a month-on-month decrease of 5.48% [3] - Tiancheng Control's subsidiary received a notification for a passenger car seat assembly project, expected to start production in April 2026 [5] - ST Huluwa obtained a drug registration certificate for Cefodizime capsules, a third-generation broad-spectrum cephalosporin [6] Group 3 - Jiulong Biotech announced the resignation of its Vice Chairman and General Manager Liang Hongjun due to work adjustments [8] - Guanhua High-tech's shareholder plans to reduce its stake by up to 17.50 million shares, not exceeding 1% of the total share capital [9] - Hebei Steel received approval to issue bonds totaling up to 10 billion yuan [10] Group 4 - Yunnan Energy Investment's subsidiaries received a total of 309 million yuan in renewable energy price subsidies [12] - Zhenghong Technology reported sales of 16,800 pigs in August, with a revenue of 22.87 million yuan, showing a year-on-year increase in sales volume of 63.31% [14] - Jilin Aodong's subsidiary received a drug registration certificate for a solution used in asthma treatment [16] Group 5 - Aonong Biological reported a 26.84% year-on-year increase in pig sales volume in August, reaching 150,100 pigs [18] - Xingdesheng announced a share repurchase plan with a budget of 15 to 30 million yuan [20] - Yueyang Lin Paper's Chairman Ye Meng resigned due to work adjustments [22] Group 6 - Kangchen Pharmaceutical's controlling shareholder plans to reduce its stake by up to 4.78 million shares, not exceeding 3% of the total share capital [23] - Changchun Yidong's General Manager Liu Xiaodong resigned due to work adjustments [25] - Zhongzai Resources' subsidiary received a government subsidy of 12.75 million yuan [26] Group 7 - Tianyu Biological reported a 41.89% month-on-month increase in sales revenue from pig sales in August [27] - Changfei Optical's shareholder Draka Comteq B.V. reduced its stake from 10% to 5% [27] - Zhongchuan Technology's Chairman Wu Xingwang resigned due to work adjustments [28] Group 8 - Huakang Clean announced a successful bid for a medical service construction project valued at 131 million yuan [29] - Yuegui Co. plans to establish a wholly-owned subsidiary with a registered capital of 100 million yuan [31] - Baisheng Intelligent's Vice General Manager and Board Secretary Huang Lijun resigned for personal reasons [32] Group 9 - Jiangsu Shuntian will change its stock name to "Suhao Fashion" starting September 10, 2025 [34] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1.3759 million shares, not exceeding 1% of the total share capital [35] - Heng Rui Pharmaceutical received approval for clinical trials of HRS-4729 injection [37] Group 10 - Changfei Optical's shareholder plans to reduce its stake by up to 110,000 shares, not exceeding 0.15% of the total share capital [39] - Yutong Bus reported sales of 4,260 vehicles in August, a year-on-year increase of 16.78% [40] - JinkoSolar received 646 million yuan in renewable energy subsidies in August, a 248% increase year-on-year [41] Group 11 - Beijing Lier signed a strategic cooperation agreement with SenseTime and Xiwang Technology for AI collaboration [43] - Gongdong Medical's controlling shareholder plans to reduce its stake by up to 3% [44] - Zhonghuan Hailu terminated its control change plan and resumed trading [46] Group 12 - Longzi Co. reported a tax payment of 22.27 million yuan due to a tax audit [48] - Guoguang Chain's controlling shareholder plans to reduce its stake by up to 2.99% [49] - Guoxin Technology successfully tested a new high-performance chip for automotive electronics [50] Group 13 - GF Securities reported a cumulative increase in borrowings exceeding 20% of its net assets [51] - China Construction Bank's subsidiary plans to increase capital by 3 billion yuan [52] - Jifeng Technology plans to establish a wholly-owned subsidiary with a capital of 50 million yuan [53] Group 14 - Jiantou Energy received approval for a stock issuance plan to specific investors [54] - Shanghai Laishi's executives plan to collectively increase their holdings by at least 6 million yuan [55] - Wencan Co. reported a fire incident at its subsidiary, with no casualties reported [56]

Market Performance - On September 5, the AI medical sector rose by 1.53%, with Yaoshi Technology leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - The top-performing stocks in the AI medical sector included: - Yaoshi Technology (300725) with a closing price of 44.21, up 3.85% [1] - ZheShu Culture (600633) with a closing price of 14.44, up 3.74% [1] - MaiDi Technology (603990) with a closing price of 14.64, up 3.24% [1] - Other notable stocks included Hongbo Pharmaceutical (301230) at 37.89, up 3.21%, and Jiahe Meikang (688246) at 31.20, up 2.80% [1] Capital Flow - The AI medical sector saw a net inflow of 56.49 million yuan from institutional investors, while retail investors experienced a net outflow of 50.12 million yuan [2] - The capital flow for specific stocks showed: - Meinian Health (002044) had a net inflow of 39.11 million yuan from institutional investors [3] - MaiDi Technology (603990) had a net inflow of 19.26 million yuan from institutional investors [3] - ZheShu Culture (600633) had a net inflow of 5.19 million yuan from institutional investors [3]

Group 1 - The core point of the news is that the major shareholder, Hongyun Jiukang Data Technology (Beijing) Co., Ltd., plans to reduce its stake in Jiahe Meikang by up to 1,375,855 shares, which is 1% of the total share capital, due to liquidity needs [1] - As of the announcement date, Hongyun Jiukang holds 8,485,931 shares, accounting for 6.17% of the total shares of Jiahe Meikang [1] - The shares to be sold were acquired before the company's initial public offering and have been tradable since December 14, 2022 [1] Group 2 - Jiahe Meikang raised a total of 1.362 billion yuan from its initial public offering, with a net amount of 1.24 billion yuan after deducting issuance costs [2] - The final net fundraising amount exceeded the original plan by 490 million yuan, which was initially set at 750 million yuan [2] - The funds raised are intended for various projects, including specialized electronic medical record development and data center upgrades [2]

Group 1 - The company is holding its fourth extraordinary general meeting of shareholders in 2025 to ensure the rights of all shareholders and maintain order during the meeting [1][2] - Shareholders and their representatives must register to attend the meeting and will have the right to speak, inquire, and vote [1][2] - The meeting will include a combination of on-site and online voting, with specific time slots for voting on the day of the meeting [4][6] Group 2 - The first agenda item is about the transfer of equity in a subsidiary, Beijing Jiahe Haishen Health Technology Co., Ltd., involving the transfer of shares from certain individuals to Xia Jun and the unconditional transfer of shares held by a wholly-owned subsidiary to the listed company [4][5] - The second agenda item involves the resignation of independent director Ren Hong and the election of Chai Jian as a candidate for independent director and committee member [5][7] - The meeting will be witnessed by a lawyer from a law firm, who will provide a legal opinion on the proceedings [3][6]

Group 1: Company Announcements - Heng Rui Medicine has received the clinical trial approval notice for HRS-4729 injection, a self-developed peptide drug targeting GLP-1R, GIPR, and GCGR receptors, with no similar products approved in the market [1] - Hubei Yihua has successfully launched its 200,000 tons/year caustic soda project, aimed at upgrading its chlor-alkali chemical industry and enhancing market competitiveness [2] - Ji Min Health announced that its shareholder, Shuangge Group, plans to reduce its stake by up to 3%, equating to a maximum of 15.75 million shares [3] - China Shipbuilding intends to absorb and merge with China Shipbuilding Industry Corporation through a share exchange, with the latter's A-shares set to be delisted on September 5, 2025 [4] - Changfei Fiber reported that its shareholder, Changjiang Communication, plans to reduce its stake by up to 0.15%, totaling no more than 1.1 million shares [5] Group 2: Strategic Collaborations and Developments - Beijing Lier has signed a strategic cooperation agreement with SenseTime and Xiwang Technology to explore AI computing power collaboration and related applications [6] - Junsheng Electronics is collaborating with leading clients like Zhiyuan Robotics, having achieved bulk supply of customized main control boards and various sensors [7][8] - Guoxin Technology has successfully tested a new generation of high-performance chips for automotive electronic BLDC motor control, aimed at addressing the MCU chip shortage in the automotive sector [9] Group 3: Other Corporate Actions - Guoguang Chain's actual controller plans to reduce their stake by up to 2.99%, totaling a maximum of 12.506 million shares [10] - Zhonghuan Hailu has terminated its control change plan, with its stock set to resume trading on September 5, 2025 [11] - Various companies have reported significant project wins, including Ningbo Construction winning contracts worth 1.117 billion yuan [12]